CPT 81228 Chromosomal Microarray Reimbursement

CPT code 81228 represents a chromosomal microarray (comparative genomic hybridization, CGH, or CMA) laboratory test that provides a high-resolution, genome-wide assessment for copy-number variants (CNVs). This molecular diagnostic is commonly used in the evaluation of developmental delay, intellectual disability, congenital anomalies, and other neurodevelopmental disorders. The test is clinically significant because it identifies submicroscopic deletions and duplications that are not visible on standard karyotype, influencing diagnosis, prognosis, genetic counseling, and care planning.

Key payers addressed in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The publication summarizes payer coverage themes, clinical context, and policy trends affecting access to microarray testing for genetic evaluation.

Readers will learn the clinical scope and utility of CPT code 81228, typical sites of service and service type, common payer coverage considerations, and where to find benchmarks and policy updates relevant to molecular cytogenetic testing. The summary provides a concise reference for billing, coding, and administrative teams, as well as clinicians seeking clarity on the role of high-resolution chromosomal microarray in genetic diagnostics. Data not available in the input is noted where applicable in detailed sections.

Billing Code Overview

CPT code 81228 describes a comparative genomic hybridization (CGH) microarray test, also known as chromosomal microarray (CMA) or molecular karyotype performed by microarray. The procedure is a high-resolution, genome-wide evaluation that detects copy-number variants (CNVs) — gains or losses of chromosomal material — that may be associated with developmental delays, congenital anomalies, or intellectual disability.

Service Type: Laboratory — Molecular Diagnostic Test

Typical Site of Service: Clinical laboratory or specialized molecular diagnostics laboratory (inpatient or outpatient specimen collection as applicable)

Clinical Context

A pediatric neurologist refers a 3-year-old child with global developmental delay, hypotonia, and speech delay for genomic evaluation. The clinician orders chromosomal microarray (CMA) testing to detect copy-number variants (CNVs) that could explain the child’s developmental disabilities. A blood specimen is collected in the outpatient phlebotomy area of a hospital-affiliated genetics clinic and sent to the molecular diagnostics laboratory. The laboratory analyst performs the technical microarray processing, hybridization, scanning, and initial data QC and reporting steps described by CPT 81228. The laboratory report is returned to the ordering clinician, who reviews results with the family in follow-up and coordinates genetic counseling or further testing as indicated.

Coding Specifications

Modifier	Description	When to Use
`26`	Professional component	Use when billing only the professional interpretation component separate from the technical laboratory work.
`TC`	Technical component	Use when billing only the technical component performed by the lab (equipment, reagents, technician time).

Taxonomy Code	Specialty	Notes
`207RG0100X`	Clinical Molecular Genetics Laboratory	Laboratory department performing CMA testing; may be listed for billing providers.
`207L00000X`	Clinical Laboratory	General clinical laboratory taxonomy applicable to labs performing molecular cytogenetics.
`2080P0004X`	Pediatric Neurology	Common ordering specialty for developmental delay evaluations.
`208000000X`	Medical Genetics	Ordering specialty for genetic evaluation and interpretation.
`363LP0800X`	Phlebotomy	Specimen collection specialty often involved in outpatient collection workflows.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`F82`	Specific developmental disorder of motor function	Motor delays may prompt CMA testing during developmental assessment.
`F84.0`	Autistic disorder	Autism spectrum disorder evaluations commonly include CMA to assess for CNVs.
`F80.1`	Expressive language disorder	Significant speech delay can be an indication to pursue genomic testing.
`R62.0`	Delayed milestone in childhood	General developmental delay frequently leads to CMA testing as part of etiology evaluation.
`G31.84`	Mild cognitive impairment, so stated	Cognitive delays or regression may prompt CMA to identify genetic causes.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`81228`	Chromosomal microarray (CMA) — comparative genomic hybridization microarray, genome-wide	Primary laboratory test performed to detect copy-number variants associated with developmental disabilities.
`81229`	Chromosomal microarray (CMA), targeted microarray analysis	Alternative CMA performed with a different design (targeted vs genome-wide); may be ordered depending on clinical indication.
`81479`	Unlisted molecular pathology procedure	Used for molecular tests not otherwise specified; rarely used when novel analysis accompanies CMA.
`88237`	Microarray analysis; interpretation and report	Sometimes used for reporting components of array testing in older coding sets; relates to interpretation and reporting.
`89240`	Isolation or extraction of DNA for genetic testing	Pre-analytic processing that may be performed prior to CMA analysis in the lab workflow.

OpenPayer

Summary & Overview

CPT 81228: Chromosomal Microarray (CGH/CMA) Molecular Karyotype